

Sub
B4

- See B3

Sub
B6

10. The method of claim 4 wherein the antibody is humanized.

11. A composition for inducing an immune response against transformed, infected or diseased tissue comprising

sub
a2
molecules binding to soluble cytokine receptor molecules, wherein the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoietin, G-CSF, M-CSF and SCF, wherein binding of the molecule prevents the soluble cytokine receptor from binding to the cytokine, in an amount effective to reduce the amount of transformed, infected, or diseased tissue, wherein the molecules are in a pharmaceutically acceptable, endotoxin free carrier or immobilized in a sterile endotoxin free extracorporeal device.

12. The composition of claim 11 wherein the device is an absorbent column selectively removing specific cytokine or cellular inhibitors from the blood.

13. The composition of claim 11 wherein the molecules are antibodies.

14. The composition of claim 13 wherein the antibodies are humanized.

15. The composition of claim 13 wherein the antibodies are fragments including the epitope binding regions.

16. The composition of claim 11 wherein the cytokine or cellular inhibitors are selected from the group consisting of soluble tissue necrosis factor receptor-1 ("sTNFR-1") and soluble tissue necrosis factor receptor-2 ("sTNFR-2").

Add B7

00011-54060260